Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium enhances the activity of antithrombin III, which accelerates the inhibition of factor Xa and, to a lesser extent, thrombin (factor IIa). This reduces thrombin generation and fibrin formation, thereby limiting the development of blood clots while preserving normal haemostatic balance.

The specific dose of Ledraxen is determined by the prescribing clinician based on the patient’s indication, weight, renal function, and overall risk profile. Healthcare professionals calculate the appropriate amount and administration schedule for each individual case.

Safety data for enoxaparin sodium in pregnancy and lactation are limited. It may be used during pregnancy only if the potential benefits justify the potential risks to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in breast milk.

To request Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with unfractionated heparin, enoxaparin sodium (Ledraxen) offers more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring in most patients. It provides a lower risk of heparin‑induced thrombocytopenia but still carries bleeding risk similar to other anticoagulants.

Ledraxen should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Ledraxen is administered by subcutaneous injection, intravenous injection, or via the haemodialysis circuit, depending on the clinical indication. The exact route, injection site and technique are determined by the prescribing clinician and nursing staff.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, heparin‑induced thrombocytopenia (HIT), and rare allergic reactions that can lead to anaphylaxis. Patients should be monitored closely for signs of bleeding or platelet count changes.

Ledraxen is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or other LMWHs, and those with severe uncontrolled hypertension. Caution is also advised for individuals with a history of HIT, recent spinal or epidural procedures, or severe renal impairment without dose adjustment.